News Medical

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

Various pandemics associated with viral pathogens have occurred in recent decades. The continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is one of the worst and has had ...
Seeking Alpha

Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences (ASMB), Inc. , a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases ...
BioWorld

AB-1659, a potent orally bioavailable NTCP inhibitor that blocks entry of HBV/HDV viruses

Researchers from Assembly Biosciences Inc. recently presented details on the discovery and preclinical evaluation of a novel small-molecule hepatitis B virus (HBV) and hepatitis D virus (HDV) entry ...
Nasdaq

New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 ...

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...